[FPRX] Five Prime Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 1.25 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 51.31 Change: 0.98 (1.95%)
Ext. hours: Change: 0 (0%)

chart FPRX

Refresh chart

Strongest Trends Summary For FPRX

FPRX is in the medium-term down -32% in 2 months. In the long-term down -73% below S&P in 2 years and down -87% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company?s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC; Glaxo Group Limited; GSK-HGS; Pfizer Inc.; and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.2 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -13.93% Sales Growth - Q/Q-7.71% P/E
P/E To EPS Growth P/S62.54 P/BV8.07 Price/Cash Per Share5.75
Price/Free Cash Flow91.69 ROA-17.73% ROE-25.73% ROI
Current Ratio11.41 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin-200.57% Net Profit Margin-199.36% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities79.58 M Cash From Investing Activities-69.81 M Cash From Operating Activities-10.55 M Gross Profit
Net Profit-11.04 M Operating Profit-11.14 M Total Assets224.57 M Total Current Assets220.33 M
Total Current Liabilities19.31 M Total Debt Total Liabilities69.8 M Total Revenue4.29 M
Technical Data
High 52 week19.47 Low 52 week8.12 Last close9.21 Last change-3.15%
RSI22.31 Average true range0.61 Beta1.42 Volume214.71 K
Simple moving average 20 days-15.12% Simple moving average 50 days-23.29% Simple moving average 200 days-24.3%
Performance Data
Performance Week-6.78% Performance Month-23.25% Performance Quart-20.47% Performance Half-18.21%
Performance Year-50.88% Performance Year-to-date-0.97% Volatility daily3.54% Volatility weekly7.91%
Volatility monthly16.21% Volatility yearly56.16% Relative Volume286.4% Average Volume303.6 K
New High New Low

News

2019-06-18 08:50:12 | Five Prime Therapeutics FPRX Looks Good: Stock Adds 9.2% in Session

2019-06-18 08:04:07 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-11 08:03:05 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-10 08:04:58 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-09 15:05:00 | Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors

2019-06-09 15:00:00 | Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

2019-06-06 08:05:08 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-04 08:05:20 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-01 09:01:00 | Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting

2019-05-24 16:01:00 | Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

2019-05-15 18:39:00 | Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors

2019-05-15 17:45:00 | Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting

2019-05-09 14:08:20 | Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-09 11:23:56 | Five Prime Therapeutics FPRX Q1 2019 Earnings Call Transcript

2019-05-08 18:45:10 | Five Prime Therapeutics FPRX Reports Q1 Loss, Misses Revenue Estimates

2019-05-08 17:39:22 | Five Prime Therapeutics: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Five Prime Therapeutics Reports First Quarter 2019 Results

2019-05-07 08:04:53 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-05-01 10:33:02 | Earnings Preview: Five Prime Therapeutics FPRX Q1 Earnings Expected to Decline

2019-04-30 09:04:35 | Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

2019-04-30 08:05:00 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-04-17 19:56:00 | Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

2019-04-17 13:27:54 | What Should You Know About Five Prime Therapeutics, Inc.'s NASDAQ:FPRX Earnings Trajectory?

2019-03-28 08:02:05 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-25 09:19:13 | Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

2019-03-19 09:28:01 | Will Five Prime Therapeutics Continue to Surge Higher?

2019-03-19 08:29:45 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-12 10:27:29 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-11 06:00:00 | Five Prime Has 5 Drugs in its Pipeline

2019-03-06 08:03:09 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-05 18:05:00 | Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

2019-03-05 08:04:58 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-27 03:02:16 | Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 21:47:48 | Five Prime Therapeutics Inc FPRX Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-25 10:30:11 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-20 20:05:00 | Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

2019-02-15 08:02:35 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-08 08:04:13 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-07 16:05:00 | Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

2019-02-04 17:05:00 | Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum

2019-01-30 23:45:02 | Why are deep-pocketed biotechs cutting hundreds of jobs?

2019-01-28 09:37:02 | MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

2019-01-24 03:13:08 | Five Prime Therapeutics, Inc. FPRX Shares March Higher, Can It Continue?

2019-01-18 08:03:43 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-01-17 14:05:00 | Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology ASCO Gastrointestinal GI Cancers Symposium

2019-01-17 08:03:57 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-01-16 07:40:00 | Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications

2019-01-15 17:08:33 | Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

2019-01-15 16:05:00 | Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities